QualityDipStocks / Health Care · Health services
Progyny PGNY
Outside our quality screen, so we don’t track its dips. It’s 9% below its 52-week high.
Outside our quality screen, trading well below our fair value estimate, 10% over its Market Value.
Worth knowing
- Share count down 11% in 2 years
From the data on this page, as of the last close. How we pick these
- Fair value est.
- $67.00+128%
- Market Value
- $26.80price +10%
- Off 52-wk high
- −9%
- Risk vs market
- Lowbeta 0.24
5 bullish · 3 bearish See why
Repriced or dip?
Near its high
The price is 9% below its 52-week high (Jul 14), but the business held up: earnings per share +19.9%, operating margin +1.1 pts, shares outstanding fewer shares, each owns more.
Some numbers held up (earnings per share +19.9%, operating margin +1.1 pts, shares outstanding fewer shares, each owns more), others slipped. The price is 9% below its 52-week high.
The price is 9% below its 52-week high, and the business changed too.
Within 10% of its 52-week high, so there is no dip to judge yet.
Data-based read, not advice.
Priced in
How much growth the market assumed at the 52-week high, the low and today (a reverse DCF).
At the high ($32.36, Jul 14) the price assumed about 2%/yr free-cash-flow growth; at the low ($16.30, Apr 10) about −10%; today about 0%. The last 3 years delivered 35%/yr (free cash flow).
Dashed line: what the last 3 years delivered, 35%/yr (free cash flow)
| High | Low | Now | |
|---|---|---|---|
| Price | $32.36Jul 14 | $16.30Apr 10 | $29.41 |
| Implied growth | +2% | −10% | 0% |
| P/E | 40.5× | 24.9× | 30.7× |
| P/FCF | 14.9× | 7.6× | 13.5× |
What this means: the higher the implied growth, the more the price already counts on. If today's number sits well below what the business has delivered, the market expects less than its track record.
How it’s computed
Reverse DCF: the same 10-year free-cash-flow model as our fair value estimate (9.5% discount rate, growth for years 1–5 fading to 3% by year 10, 3% after), solved for the growth that makes it equal the market value at each price. For the high and the low we use only the filings that were public on that day, so nothing from a later report leaks back. Market value = that close × diluted shares. P/E = market value / 12-month net income; Price / FCF = market value / 12-month free cash flow; EV / Sales = (market value + debt − cash) / 12-month revenue. Hidden when the share count moved over 20% (split, merger), free cash flow is negative, or the company reports in another currency.
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
How the range is computed
Ten-year free-cash-flow DCF. Same 10-year free-cash-flow model as the base: discount rate 9.5% ±1 point and growth 15.0% ±2 points. Bear = 10.5% and 13.0%; bull = 8.5% and 17.0% (both fade to 3%). A model estimate from public filings, not a forecast of where the price will go.
Price is below even the bear case.
Cyclical / peak cash flow — treat with care
What the price implies To be worth today’s price, PGNY’s free cash flow would need to stay flat for five years; our estimate uses 15%.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much PGNY moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Has moved mostly independently of the market, but its own price swings are 4.2× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.24
- Volatility
- 54% vs 13% SPY
- Correlation SPY
- 0.06
- Correlation QQQ
- 0.04
How it ranks
Where PGNY stands vs every one of the 1,996 stocks we cover that has the number. Longer bar = better.
Top quarter on 3 of 5 measures
- Discount to fair value estimate128% · price below our base caseTop 5%of 1,314
- Free cash flow yield7.4% · free cash flow vs market capTop 21%of 1,391
- Dividends + buybacks yield9.5% · cash paid out or used to retire shares, vs market capTop 7%of 1,836
- Revenue growth, last 12 months+5.5% · vs the 12 months beforeLowest 31%of 1,814
- Operating margin8.6% · of sales kept as operating profitLowest 38%of 1,288
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
DCF $67.00 · MV $26.80 · FCF value $63.93
Cyclical / peak cash flow — treat with care
Assumes 15.0% growth for 5 years (revenue grew 17.9% a year FY22–FY25; capped at 15%), fading to 3%; 9.5% discount rate, 3% terminal growth. FCF base $2.17 a share (trailing 12 months to Jun 30, 2026), from the 10-Q filed Aug 7, 2026.
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 5 of 5
ValuationOur DCF fair value estimate is $67.00, 128% above the price (cyclical or peak cash flow, so treat with care).
Cash returnsShare count down 8.4% in a year: $230M of buybacks over 12 months.
ValuationFree-cash-flow yield of 7.4% (price / FCF 13.5×): $178M of free cash in the last 12 months.
GrowthSales compounded 18% a year from FY2022 to FY2025.
ProfitabilityReturn on equity of 16% over the last 12 months.
Top bearish points 3 of 5
GrowthSales growth slowed to 6% over the last 12 months, from 18% a year over the prior three fiscal years.
ProfitabilityGross margin of 25%, below the 62% median for the 146 Health Care companies we cover.
ValuationTrades 9.7% above its Market Value of $26.80, the average price paid since the Aug 6 filing.
All fundamentals
P/E 30.7 · FCF yield 7.4% · ROE 16%
Valuation
- P/E
- 30.7×Health Care median 29.0×
- Price / FCF
- 13.5×
- FCF yield
- 7.4%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 1.84×
- Price / book
- 5.33×
- Market cap
- $2.4Bprice × diluted shares
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $1.3B
- Sales growth, 12 months
- +5.5%vs the 12 months before
- Sales growth, 3 yrs
- +17.9%/yrfrom FY2022
- Diluted EPS, 12 months
- $0.92
- EPS growth, last FY
- +14.0%
- Net income, 12 months
- $79M
- Net income growth
- +48%12 months vs before
Profitability
- Gross margin
- 24.6%
- Operating margin
- 8.6%
- Net margin
- 6.0%
- FCF margin
- 13.6%
- Return on equity
- 16%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $237M
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- $178M
- FCF growth, 12 months
- −6%
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- $230M9.5% of market cap
- Share count, 1 year
- −8.4%diluted shares vs a year ago
- Stock-based comp
- $107M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From Progyny’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $0.2B · Sales +5%
- Free cash flow, 12 months$0.2B
- Free-cash-flow yield7.4%
- Free-cash-flow margin15%
- Gross margin25%
- Operating margin11%
- Return on invested capital49%
- Return on equity16%
- Sales growth (latest quarter vs year-ago quarter)+5%
- Net debt / EBITDA−1.7×
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $29.41
- 52-wk lowlowest close, 1 year$16.30−44.6%
- Market Valueavg paid since Aug 6$26.80−8.9%
- PriceMon Nov 2 close$29.41you are here
- 52-wk highhighest close, 1 year$32.36+10.0%
- Fair value est.base case$67.00+127.8%
Momentum & 52-week range
RSI 63 · 5 days +4.6%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Next report
Nov 4
- DateWed Nov 4, after the close
- Consensus EPS$0.27
- Year-ago EPS$0.15
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
PGNY is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Progyny in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 1:01 PM ET.
Compare with peers
Closest in size in Health services
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.